Latest:
Dr. Aisner on the Limitations of Molecular Profiling
Dara L. Aisner, MD, PhD, associate professor in the department of Pathology at the University of Colorado School of Medicine, discusses the limitations of molecular profiling.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Darcy Lewis
Latest:
Breast Cancer Expert Focuses on Decoding Biomarkers
For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.
Dario C. Altieri, MD
Latest:
Institute Develops Fresh Bench-to-Bedside Model Through Community Ties
In more than 40 years as a National Cancer Institute (NCI)-designated cancer center-and the first center in the network devoted purely to basic research-The Wistar Institute has built a reputation for furthering the sort of scientific research that will improve clinical cancer medicine.
Davendra Sohal, MD, MPH
Latest:
Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials
Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
David A. Braun, MD, PhD
David A. Braun, MD, PhD, is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center
Latest:
Dr Braun on Fundamental Immune Defects in Chromophobe RCC
David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.
David Arenberg, MD
Latest:
Dr. Arenberg on Low-Cost Intervention to Improve Tobacco Cessation for Lung Cancer
David Arenberg, MD, associate professor, Department of Internal Medicine at the University of Michigan, discusses preliminary results of a low-cost intervention to improve tobacco cessation practices within a large university health system.
David C. Fryefield, MD
Latest:
Developing Alternative Payment Models That Providers and Commercial Payers Support
Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.